» Articles » PMID: 28473642

Selective Vulnerability of Striatal D2 Versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice

Overview
Journal J Neurosci
Specialty Neurology
Date 2017 May 6
PMID 28473642
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Despite marked regional differences in HIV susceptibility within the CNS, there has been surprisingly little exploration into the differential vulnerability among neuron types and the circuits they underlie. The dorsal striatum is especially susceptible, harboring high viral loads and displaying marked neuropathology, with motor impairment a frequent manifestation of chronic infection. However, little is known about the response of individual striatal neuron types to HIV or how this disrupts function. Therefore, we investigated the morphological and electrophysiological effects of HIV-1 -activator of transcription (Tat) in dopamine subtype 1 (D1) and dopamine subtype 2 (D2) receptor-expressing striatal medium spiny neurons (MSNs) by breeding transgenic Tat-expressing mice to -tdTomato- or -eGFP-reporter mice. An additional goal was to examine neuronal vulnerability early during the degenerative process to gain insight into key events underlying the neuropathogenesis. In D2 MSNs, exposure to HIV-1 Tat reduced dendritic spine density significantly, increased dendritic damage (characterized by swellings/varicosities), and dysregulated neuronal excitability (decreased firing at 200-300 pA and increased firing rates at 450 pA), whereas insignificant morphologic and electrophysiological consequences were observed in Tat-exposed D1 MSNs. These changes were concomitant with an increased anxiety-like behavioral profile (lower latencies to enter a dark chamber in a light-dark transition task, a greater frequency of light-dark transitions, and reduced rearing time in an open field), whereas locomotor behavior was unaffected by 2 weeks of Tat induction. Our findings suggest that D2 MSNs and a specific subset of neural circuits within the dorsal striatum are preferentially vulnerable to HIV-1. Despite combination antiretroviral therapy (cART), neurocognitive disorders afflict 30-50% of HIV-infected individuals and synaptodendritic injury remains evident in specific brain regions such as the dorsal striatum. A possible explanation for the sustained neuronal injury is that the neurotoxic HIV-1 regulatory protein -activator of transcription (Tat) continues to be expressed in virally suppressed patients on cART. Using inducible Tat-expressing transgenic mice, we found that dopamine subtype 2 (D2) receptor-expressing medium spiny neurons (MSNs) are selectively vulnerable to Tat exposure compared with D1 receptor-expressing MSNs. This includes Tat-induced reductions in D2 MSN dendritic spine density, increased dendritic damage, and disruptions in neuronal excitability, which coincide with elevated anxiety-like behavior. These data suggest that D2 MSNs and specific circuits within the basal ganglia are preferentially vulnerable to HIV-1.

Citing Articles

A helping HAND: therapeutic potential of MAGL inhibition against HIV-1-associated neuroinflammation.

League A, Yadav-Samudrala B, Kolagani R, Cline C, Jacobs I, Manke J Front Immunol. 2024; 15:1374301.

PMID: 38835765 PMC: 11148243. DOI: 10.3389/fimmu.2024.1374301.


EcoHIV Infection Modulates the Effects of Cocaine Exposure Pattern and Abstinence on Cocaine Seeking and Neuroimmune Protein Expression in Male Mice.

Namba M, Xie Q, Park K, Jackson J, Barker J bioRxiv. 2024; .

PMID: 38659915 PMC: 11042347. DOI: 10.1101/2024.04.15.589615.


Astrocytes: Role in pathogenesis and effect of commonly misused drugs in the HIV infected brain.

Pla-Tenorio J, Roig A, Garcia-Cesani P, Santiago L, Sepulveda-Orengo M, Noel Jr R Curr Res Neurobiol. 2023; 5:100108.

PMID: 38020814 PMC: 10663134. DOI: 10.1016/j.crneur.2023.100108.


Contemporary Antiretroviral Therapy Dysregulates Iron Transport and Augments Mitochondrial Dysfunction in HIV-Infected Human Microglia and Neural-Lineage Cells.

Kaur H, Minchella P, Alvarez-Carbonell D, Purandare N, Nagampalli V, Blankenberg D Int J Mol Sci. 2023; 24(15).

PMID: 37569616 PMC: 10419149. DOI: 10.3390/ijms241512242.


Advancing the preclinical study of comorbid neuroHIV and substance use disorders: Current perspectives and future directions.

Namba M, Xie Q, Barker J Brain Behav Immun. 2023; 113:453-475.

PMID: 37567486 PMC: 10528352. DOI: 10.1016/j.bbi.2023.07.021.


References
1.
Ehrlich M . Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics. 2012; 9(2):270-84. PMC: 3337013. DOI: 10.1007/s13311-012-0112-2. View

2.
Fitting S, Xu R, Bull C, Buch S, El-Hage N, Nath A . Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol. 2010; 177(3):1397-410. PMC: 2928972. DOI: 10.2353/ajpath.2010.090945. View

3.
Cardoso F . HIV-related movement disorders: epidemiology, pathogenesis and management. CNS Drugs. 2002; 16(10):663-8. DOI: 10.2165/00023210-200216100-00002. View

4.
Augood S, Faull R, Emson P . Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol. 1997; 42(2):215-21. DOI: 10.1002/ana.410420213. View

5.
Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M . HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem. 2000; 275(6):4159-65. DOI: 10.1074/jbc.275.6.4159. View